[go: up one dir, main page]

DK3457135T3 - Behandlingsmuligheder til fabrys sygdom - Google Patents

Behandlingsmuligheder til fabrys sygdom Download PDF

Info

Publication number
DK3457135T3
DK3457135T3 DK18197135.9T DK18197135T DK3457135T3 DK 3457135 T3 DK3457135 T3 DK 3457135T3 DK 18197135 T DK18197135 T DK 18197135T DK 3457135 T3 DK3457135 T3 DK 3457135T3
Authority
DK
Denmark
Prior art keywords
treatment options
fabrys
disease
fabrys disease
options
Prior art date
Application number
DK18197135.9T
Other languages
English (en)
Inventor
David Lockhart
Jeff Castelli
Original Assignee
Amicus Therapeutics Inc
Nat Institutes Of Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38723987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3457135(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amicus Therapeutics Inc, Nat Institutes Of Health filed Critical Amicus Therapeutics Inc
Application granted granted Critical
Publication of DK3457135T3 publication Critical patent/DK3457135T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/94—Hydrolases (3) acting on glycosyl compounds (3.2) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/04—Endocrine or metabolic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Ecology (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK18197135.9T 2006-05-16 2007-05-16 Behandlingsmuligheder til fabrys sygdom DK3457135T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80108906P 2006-05-16 2006-05-16
US85363106P 2006-10-23 2006-10-23
EP15173515.6A EP2955520B1 (en) 2006-05-16 2007-05-16 Treatment options for fabry disease

Publications (1)

Publication Number Publication Date
DK3457135T3 true DK3457135T3 (da) 2025-02-24

Family

ID=38723987

Family Applications (3)

Application Number Title Priority Date Filing Date
DK12168451.8T DK2533050T6 (da) 2006-05-16 2007-05-16 Behandlingsmuligheder ved Fabrys sygdom
DK14168748.3T DK2787345T3 (da) 2006-05-16 2007-05-16 Behandlingsmuligheder for fabrys sygdom
DK18197135.9T DK3457135T3 (da) 2006-05-16 2007-05-16 Behandlingsmuligheder til fabrys sygdom

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK12168451.8T DK2533050T6 (da) 2006-05-16 2007-05-16 Behandlingsmuligheder ved Fabrys sygdom
DK14168748.3T DK2787345T3 (da) 2006-05-16 2007-05-16 Behandlingsmuligheder for fabrys sygdom

Country Status (19)

Country Link
US (9) US7851143B2 (da)
EP (6) EP4541418A3 (da)
JP (7) JP2009537149A (da)
AU (1) AU2007253900A1 (da)
CA (1) CA2652553C (da)
CY (3) CY1115180T1 (da)
DK (3) DK2533050T6 (da)
ES (4) ES2573498T3 (da)
FI (1) FI3457135T3 (da)
HK (1) HK1218955A1 (da)
HU (3) HUE027569T2 (da)
LT (2) LT3457135T (da)
LU (1) LU93312I2 (da)
MX (2) MX351004B (da)
NL (1) NL300843I2 (da)
PL (3) PL2533050T6 (da)
PT (2) PT3457135T (da)
SI (3) SI3457135T1 (da)
WO (1) WO2007137072A2 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4541418A3 (en) 2006-05-16 2025-07-09 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
MX2009011473A (es) * 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
PL2252313T3 (pl) 2008-02-12 2015-09-30 Amicus Therapeutics Inc Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi
MX2010009875A (es) * 2008-03-12 2010-11-26 Amicus Therapeutics Inc Ensayos para diagnosticar y evaluar opciones de tratamiento para enfermedad de pompe.
WO2011063048A2 (en) * 2009-11-17 2011-05-26 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
AU2011223706A1 (en) * 2010-03-05 2012-09-20 Baylor Research Institute Involvement of androgen/androgen receptor pathway in Fabry disease
EP3698792A1 (en) * 2011-03-11 2020-08-26 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
WO2012154967A1 (en) 2011-05-12 2012-11-15 Proteostasis Therapeutics, Inc. Proteostasis regulators
JP6320931B2 (ja) * 2011-12-22 2018-05-09 セントジーン アイピー ゲーエムベーハー リソソーム酵素を再構成する能力を有する化合物ならびにアンブロキソールおよび／またはアンブロキソールの誘導体の組み合わせ
JP2015504919A (ja) 2012-01-25 2015-02-16 プロテオステイシス セラピューティクス，インコーポレイテッド プロテアソーム活性を調節する化合物
WO2014127038A1 (en) * 2013-02-12 2014-08-21 Baylor Research Institute Methods and compositions related to calcium homeostasis and fabry disease
JP6546923B2 (ja) * 2013-12-23 2019-07-17 ビーシーエヌ ペプタイズ エセ．ア．Ｂｃｎ Ｐｅｐｔｉｄｅｓ Ｓ．Ａ． リソソーム蓄積障害または糖原病の処置における使用のためのエキソサイトーシス活性化化合物としてのビカルタミド類似体または（ｓ）−ビカルタミド
US9675627B2 (en) * 2014-04-14 2017-06-13 Amicus Therapeutics, Inc. Dosing regimens for treating and/or preventing cerebral amyloidoses
ES2715889T3 (es) 2014-07-25 2019-06-06 Shire Human Genetic Therapies Estructura cristalina del dominio de tipo proteína de transferencia de glicolípidos de la proteína adaptadora de cuatro fosfatos 2 humana
GB201508025D0 (en) 2015-05-11 2015-06-24 Ucl Business Plc Fabry disease gene therapy
US12070453B2 (en) * 2016-07-19 2024-08-27 Amicus Therapeutics, Inc. Treatment of Fabry disease in ERT-naïve and ERT-experienced patients
US12020820B1 (en) 2017-03-03 2024-06-25 Cerner Innovation, Inc. Predicting sphingolipidoses (fabry's disease) and decision support
US11335461B1 (en) 2017-03-06 2022-05-17 Cerner Innovation, Inc. Predicting glycogen storage diseases (Pompe disease) and decision support
MX391565B (es) 2017-05-30 2025-03-21 Amicus Therapeutics Inc Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
TWI795408B (zh) * 2017-05-30 2023-03-11 美商阿米庫斯醫療股份有限公司 治療有腎損傷的法布里患者的方法
US11923048B1 (en) 2017-10-03 2024-03-05 Cerner Innovation, Inc. Determining mucopolysaccharidoses and decision support tool
HUE064761T2 (hu) * 2018-02-06 2024-04-28 Amicus Therapeutics Inc Klasszikus FABRY-betegségben szenvedõ betegek kezelése migalasztáttal
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
AU2019295765B2 (en) 2018-06-27 2024-08-29 Yumanity, Inc. Proteasome activity enhancing compounds
CN112585130A (zh) 2018-06-27 2021-03-30 蛋白质平衡治疗股份有限公司 蛋白酶体活性增强化合物
US20220184185A1 (en) 2018-07-25 2022-06-16 Modernatx, Inc. Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders
EP3851105A3 (en) 2019-08-07 2021-10-13 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
US11191827B1 (en) * 2020-12-09 2021-12-07 Tevogen Bio Inc. COVID-19 peptide specific T-cells and methods of treating and preventing COVID-19
US11623916B2 (en) 2020-12-16 2023-04-11 Amicus Therapeutics, Inc. Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990011353A1 (en) * 1989-03-24 1990-10-04 Research Corporation Technologies, Inc. Recombinant alpha-galactosidase, a therapy for fabry disease
CA2086413A1 (en) 1990-06-29 1991-12-30 Yohji Ezure Piperidine derivatives
US5900360A (en) 1996-04-10 1999-05-04 Welch; William J. Correction of genetic defects using chemical chaperones
US6270954B1 (en) 1996-04-10 2001-08-07 The Regents Of The University Of California Correction of genetic defects using chemical chaperones
US6274597B1 (en) 1998-06-01 2001-08-14 Mount Sinai School Of Medicine Of New York University Method of enhancing lysosomal α-Galactosidase A
US7842470B2 (en) 2001-10-09 2010-11-30 Oregon Health & Science University Method for pharmacoperones correction of GnRHR mutant protein misfolding
ES2531478T3 (es) 2003-01-31 2015-03-16 The Mount Sinai School Of Medicine Of New York University Terapia de combinación para tratar trastornos de deficiencia de proteínas
US7446098B2 (en) * 2003-02-18 2008-11-04 Mount Sinai School Of Medicine Of New York University Combination therapy for treating protein deficiencies
US20070066543A1 (en) 2003-05-22 2007-03-22 The Hospital For Sick Children Treatment of tay sachs or sandhoff diseases by enhancing hexosaminidase activity
FR2861991B1 (fr) 2003-11-07 2008-01-18 Centre Nat Rech Scient Utilisation d'inhibiteurs de glucosidase pour une therapie de la mucoviscidose
CN1901907A (zh) 2003-11-12 2007-01-24 阿米库斯治疗学公司 用于治疗戈谢病的葡糖并咪唑和多羟基环己烯基胺衍生物
WO2006125141A2 (en) 2005-05-17 2006-11-23 Amicus Therapeutics, Inc. A method for the treatment of pompe disease using 1-deoxynojirimycin derivatives
ES2537089T3 (es) 2005-06-08 2015-06-02 Amicus Therapeutics, Inc. Purificación de imino- y amino-azúcares
CA2611011C (en) 2005-06-08 2014-01-28 Amicus Therapeutics, Inc. Treatment of cns disorders associated with mutations in genes encoding lysosomal enzymes
NZ565953A (en) 2005-07-27 2012-01-12 Univ Florida Small compounds that correct protein misfolding and uses thereof
EP1982189A4 (en) 2006-01-27 2010-09-08 Univ Leland Stanford Junior COMPOSITIONS AND METHODS FOR SCREENING WITH HIGH PASSAGE OF PHARMACOLOGICAL CHAPTERS
EP4541418A3 (en) * 2006-05-16 2025-07-09 Amicus Therapeutics, Inc. Assays for diagnosing and evaluating treatment options for fabry disease
WO2008034628A1 (en) 2006-09-22 2008-03-27 Krka, Tovarna Zdravil, D.D., Novo Mesto Aripiprazole hemifumarate and process for its preparation
WO2008121826A2 (en) 2007-03-30 2008-10-09 Amicus Therapeutics, Inc. Method for the treatment of fabry disease using pharmacological chaperones
US9999618B2 (en) 2007-04-26 2018-06-19 Amicus Therapeutics, Inc. Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
MX2009011473A (es) 2007-04-26 2010-01-18 Amicus Therapeutics Inc Regimenes de dosificacion para el tratamiento de enfermedades por almacenamiento lisosomal que utilizan chaperonas farmacologicas.
PL2252313T3 (pl) 2008-02-12 2015-09-30 Amicus Therapeutics Inc Sposób przewidywania odpowiedzi na leczenie chorób farmakologicznymi białkami chaperonowymi
US8321148B2 (en) 2008-10-24 2012-11-27 Amicus Therapeutics, Inc. Multiple compartment dosing model
US9206457B2 (en) 2009-05-26 2015-12-08 Amicus Therapeutics, Inc. Utilization of pharmacological chaperones to improve manufacturing and purification of biologics
US20110070643A1 (en) 2009-05-26 2011-03-24 Do Hung V Utilization of Pharmacological Chaperones to Improve Manufacturing and Purification of Biologics
WO2011063048A2 (en) 2009-11-17 2011-05-26 Baylor Research Institute Urinary triaosylceramide (gb3) as a marker of cardiac disease
EP3698792A1 (en) 2011-03-11 2020-08-26 Amicus Therapeutics, Inc. Dosing regimens for the treatment of fabry disease
EP2874648A4 (en) 2012-07-17 2015-12-30 Amicus Therapeutics Inc CO-FORMULATION OF ALPHA-GALACTOSIDASE A AND 1-DEOXYGALACTONOJIRIMYCIN
US10155027B2 (en) 2012-07-17 2018-12-18 Amicus Therapeutics, Inc. Alpha-galactosidase A and 1-deoxygalactonojirimycin co-formulation for the treatment of fabry disease
EP3432882B1 (en) 2016-03-22 2021-09-01 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
US12070453B2 (en) 2016-07-19 2024-08-27 Amicus Therapeutics, Inc. Treatment of Fabry disease in ERT-naïve and ERT-experienced patients
JP2020503900A (ja) 2017-01-10 2020-02-06 アミカス セラピューティックス インコーポレイテッド ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
MX391565B (es) 2017-05-30 2025-03-21 Amicus Therapeutics Inc Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal.
EA202090242A1 (ru) 2017-07-19 2020-05-26 Амикус Терапьютикс, Инк. Лечение болезни фабри у фзт-наивных и фзт-леченных пациентов
TWI845479B (zh) 2017-08-28 2024-06-21 美商阿米庫斯醫療股份有限公司 增強及/或穩定Fabry氏症患者之心臟功能之方法
KR20200128676A (ko) 2018-02-06 2020-11-16 아미쿠스 세라퓨틱스, 인코포레이티드 임신 환자의 파브리병 치료를 위한 미갈라스타트의 용도
HUE064761T2 (hu) 2018-02-06 2024-04-28 Amicus Therapeutics Inc Klasszikus FABRY-betegségben szenvedõ betegek kezelése migalasztáttal
CA3110065A1 (en) 2018-08-20 2020-02-27 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene
EA202290024A1 (ru) 2019-06-11 2022-03-14 Амикус Терапьютикс, Инк. Способы лечения болезни фабри у пациентов с почечной недостаточностью
EP3851105A3 (en) 2019-08-07 2021-10-13 Amicus Therapeutics, Inc. Methods of treating fabry disease in patients having a mutation in the gla gene

Also Published As

Publication number Publication date
SI2533050T1 (sl) 2014-07-31
HUS1600048I1 (hu) 2017-01-30
CY2016040I1 (el) 2017-06-28
US20220160690A1 (en) 2022-05-26
ES3012794T3 (en) 2025-04-10
EP2955520A1 (en) 2015-12-16
EP2533050A1 (en) 2012-12-12
JP2009537149A (ja) 2009-10-29
US10406143B2 (en) 2019-09-10
LTC2787345I2 (lt) 2017-10-10
EP4541418A2 (en) 2025-04-23
HUE027569T2 (en) 2016-10-28
JP7175297B2 (ja) 2022-11-18
PL2533050T3 (pl) 2014-08-29
HK1178975A1 (en) 2013-09-19
EP2787345B1 (en) 2016-02-24
JP2016006088A (ja) 2016-01-14
JP2023027053A (ja) 2023-03-01
PL2787345T3 (pl) 2016-08-31
FI3457135T3 (fi) 2025-03-08
PT3457135T (pt) 2025-02-04
ES2464527T9 (es) 2015-07-24
ES2464527T3 (es) 2014-06-03
US20150238474A1 (en) 2015-08-27
EP4541418A3 (en) 2025-07-09
US20190388409A1 (en) 2019-12-26
DK2787345T3 (da) 2016-05-30
AU2007253900A1 (en) 2007-11-29
EP2955520B1 (en) 2018-10-31
CA2652553C (en) 2020-08-18
EP2787345A1 (en) 2014-10-08
WO2007137072A2 (en) 2007-11-29
JP2018138564A (ja) 2018-09-06
US11241422B2 (en) 2022-02-08
US20170042868A1 (en) 2017-02-16
MX351004B (es) 2017-09-26
US9000011B2 (en) 2015-04-07
US20080056994A1 (en) 2008-03-06
LTPA2016033I1 (lt) 2016-12-12
CY2016040I2 (el) 2017-06-28
ES2573498T3 (es) 2016-06-08
DK2533050T3 (da) 2014-06-02
HUE071237T2 (hu) 2025-08-28
LU93312I2 (fr) 2017-01-26
WO2007137072A3 (en) 2008-10-16
EP2787345B8 (en) 2016-04-13
US20120220632A1 (en) 2012-08-30
JP2013100307A (ja) 2013-05-23
SI3457135T1 (sl) 2025-07-31
JP6800176B2 (ja) 2020-12-16
LT3457135T (lt) 2025-05-12
ES2709445T3 (es) 2019-04-16
JP2020196717A (ja) 2020-12-10
MX2008014679A (es) 2009-04-14
US10383864B2 (en) 2019-08-20
US20180325881A1 (en) 2018-11-15
PT2533050E (pt) 2014-05-26
HK1218955A1 (en) 2017-03-17
EP2024745A4 (en) 2010-03-17
JP2025060691A (ja) 2025-04-10
EP2024745A2 (en) 2009-02-18
US20110104727A1 (en) 2011-05-05
EP3457135A1 (en) 2019-03-20
HK1129458A1 (en) 2009-11-27
EP3457135B1 (en) 2024-12-04
CY1115180T1 (el) 2016-12-14
EP2533050B1 (en) 2014-03-12
CY1117656T1 (el) 2017-05-17
NL300843I2 (da) 2016-12-21
US7851143B2 (en) 2010-12-14
SI2787345T1 (sl) 2016-08-31
CA2652553A1 (en) 2007-11-29
DK2533050T6 (da) 2015-09-21
PL2533050T6 (pl) 2016-05-31
US20180250279A1 (en) 2018-09-06
PL3457135T3 (pl) 2025-06-09
US9480682B2 (en) 2016-11-01
JP6026268B2 (ja) 2016-11-16
ES2464527T7 (es) 2015-09-14
EP2024745B1 (en) 2015-07-08
EP2533050B3 (en) 2015-06-24
US9987263B2 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
DK3457135T3 (da) Behandlingsmuligheder til fabrys sygdom
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK2041139T3 (da) Farmaceutiske forbindelser
ES1063346Y (es) Andador
DK1986650T3 (da) Manipulationssikre doserignsformer
DK1879623T3 (da) Genterapi til rygmarvssygdomme
EP1985195A4 (en) SHOE
DK2035369T3 (da) Terapeutiske
DK1993589T3 (da) Behandlinger for neurologiske sygdomme
DK2173831T3 (da) Brøndbehandling
BRPI0810559A2 (pt) Macadores de doenças
FI20065652L (fi) Jalkine
DK2020845T3 (da) Fremgangsmåde til høstning
BRPI0818598A2 (pt) agentes terapêuticos - 802
DE602007003905D1 (de) Verbinder
DE602007001119D1 (de) Verbinder
DE602007001118D1 (de) Verbinder
BRPI0912193A2 (pt) compostos terapêuticos.
BRPI0812105A2 (pt) Neramexano para o tratamento de nistagmo
BRPI0811781A2 (pt) Compostos de ((fenil) imidazolil)metilquinolinila terapêuticos.
ITMI20060760A1 (it) Procedimento per il trattamento di tessuti
ES1063616Y (es) Calzado
ES1063530Y (es) Calzado
UA15109S (uk) Футляр для медичних пристроїв
ES1063469Y (es) Zapatilla perfeccionada